Nektar Therapeutics NKTR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's additional paid-in capital?
- Nektar Therapeutics (NKTR) reported additional paid-in capital of $4.38B in Q1 2026.
- How has Nektar Therapeutics's additional paid-in capital changed year-over-year?
- Nektar Therapeutics's additional paid-in capital increased by 19.6% year-over-year, from $3.66B to $4.38B.
- What is the long-term trend for Nektar Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Nektar Therapeutics's additional paid-in capital has grown at a 2.6% compound annual growth rate (CAGR), from $3.39B to $3.85B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.